Major depressive disorder, recurrent severe without psychotic features. Major depressive disorder, recurrent severe without psychotic features
Conditions
Interventions
Intervention 1: The intervention group: The group received a daily dose of 50 mg of sertraline at the start of treatment. At week 2, 4 and 8, the group received a dose of sertraline (maximum dose of 2
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: in this clinical trial the patients aged 20-60 years that were refered to Yahyanejad Clinic selected. patients depressive disorder according to the DSM 5 & hamilton -depression scale more than 22
Exclusion criteria
Exclusion criteria: 1.prssence of another diagnose in axis /2. use of anti depressant medication before 1 month/3.the history of ECT during 2 months later /4.suicide ideation /homicidal ideation /5.substance or alcohal use or abuse (exceps nicotion)/6.presence of any life-threatening condition or disorder./7.pregnancy or lactation 8.age under 20 and over 60 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of memantine on depression is measured using the Hamilton Depression Rating Scale at intervals before the onset of treatment and in the second week. Timepoint: the first visit & week 2. Method of measurement: the hamilton depression rating scale (HAM-D). | — |
Secondary
| Measure | Time frame |
|---|---|
| Also, at the fourth and eighth week after the start of treatment, the response to treatment will be measured using the Hamilton Depression Rating Scale . Timepoint: Fourth and eighth weeks. Method of measurement: Hamilton Depression Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAngella hamidia
Babol University of Medical Sciences
Outcome results
None listed